Key Numbers

  • 78/80 events — patients left to complete the REGAL trial (r/wallstreetbets)
  • 16.3 months — median overall survival in Phase 2 CR2 AML trial (r/wallstreetbets)
  • 5.4 months — control arm median overall survival in same trial (r/wallstreetbets)

Bottom Line

The REGAL trial is down to its final two patients. Investors should brace for a sharp, binary price move when the data are released.

The REGAL trial for SLS’s GPS drug has reached 78 of 80 required events as of early May 2026. The imminent read‑out could trigger a decisive swing in SLS stock, rewarding those positioned for a breakout or penalizing the over‑exposed.

Why This Matters to You

If you own SLS shares, the pending data could double or erase your position in a single day. Traders with options should consider tight‑priced contracts to capture the volatility spike.

Binary Outcome Looms as Trial Wraps Up

The REGAL study’s primary endpoint hinges on event‑driven analysis; with 78 of 80 events already recorded, the outcome hinges on the last two patients.

This near‑completion mirrors the Phase 2 CR2 AML trial, where GPS boosted median overall survival to 16.3 months versus 5.4 months for control (r/wallstreetbets). The stark survival gap signals high therapeutic promise.

Potential Catalysts for a Price Surge

Historical precedent shows that late‑stage oncology read‑outs can move small‑cap stocks 30%+ in a single session (Analyst view — JPMorgan). The market will price in the survival benefit and any regulatory commentary.

Because the trial is event‑driven, the timing of the final data release is more certain than many biotech milestones, sharpening the trade window.

Risk Management Strategies for the Upcoming Release

Given the binary nature, a straddle or strangle using near‑term options can capture upside while limiting downside (Analyst view — Morgan Stanley). Position sizes should reflect the high implied volatility expected.

Investors holding the stock outright should set stop‑losses just below the recent support level of $7.20 to protect against a negative read‑out.

What to Watch

  • Watch SLS final REGAL data release (mid‑May 2026) — binary outcome could swing price dramatically (this week)
  • Monitor FDA advisory committee meeting on GPS (June 2026) — positive feedback may extend upside (next month)
  • Track comparable AML trial results from competitor firms (Q3 2026) — could influence relative valuation (Q3 2026)
Bull CaseBear Case
Data confirm a survival advantage similar to Phase 2, sparking a >30% rally.Data fall short of Phase 2 benchmark, triggering a sharp sell‑off.

Will you position for the binary swing now, or wait for the data to unfold?

Key Terms
  • Event‑driven trial — a study that concludes once a pre‑set number of clinical events (e.g., deaths) occur.
  • Median overall survival — the middle point of survival times; half the patients live longer, half shorter.
  • Straddle — an options strategy buying both a call and a put at the same strike to profit from large moves.